Lucas Van Aelst

Lucas Van Aelst

Auto-generated profile, based on publicly available information

Lucas Van Aelst

Department of Cardiology, University Hospitals Leuven, Leuven, Belgium; Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DLDorien Laenens
Dorien Laenens
YYYuling Yu
Yuling Yu
BSBéatrice Santens
Béatrice Santens
JJJohanna Jacobs
Johanna Jacobs
BBBenoit Beuselinck
Benoit Beuselinck
LALucas Van Aelst
Lucas Van Aelst
PURPOSE: In rare cases, immune checkpoint inhibitors (ICIs) cause immune-mediated myocarditis. However, true incidence of other major adverse cardiovascular events (MACEs) after ICI treatment remains unknown, mainly because late occurring side effects are rarely reported in prospective clinical trials. The aims of this study were (1) to identify incidence and risk factors of MACE in a real-life ICI-treated cancer cohort and (2) to compare incidence rates with patients with cancer who are not treated with ICIs and population controls. METHODS: In total, 672 patients treated with ICIs were included. The primary end point was MACE, a composite of acute coronary syndrome, heart failure (HF), stroke, and transient ischemic attack. Secondary outcomes were acute coronary syndrome and HF separately. Incidence rates were compared between groups after matching according to age, sex, cardiovascular history, and cancer type. RESULTS: The incidence of MACE was 10.3% during a median follow-up of 13 (interquartile range, 6-22) months. In multivariable analysis, a history of HF (hazard ratio 2.27; 95% CI, 1.03 to 5.04; P = .043) and valvular heart disease (hazard ratio 3.01; 95% CI, 1.05 to 8.66; P = .041) remained significantly associated with MACE. Cumulative incidence rates were significantly higher in the ICI group compared with the cancer cohort not exposed to ICI and the population controls, mainly driven by a higher risk of HF events. CONCLUSION: Cardiovascular events during and after ICI treatment are more common than currently appreciated. Patients at risk are those with a history of cardiovascular disease. Compared with matched cancer and population controls, MACE incidence rates are significantly higher, suggesting a potential harmful effect of ICI treatment besides the underlying risk.

18 April 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
JJJohanna E. J. Jacobs
Johanna E. J. Jacobs
Wouter L'HoyesWouter L'Hoyes
Wouter L'Hoyes
LLLieselotte Lauwens
Lieselotte Lauwens
YYYu‐Ling Yu
Yu‐Ling Yu
MBMarius Brusselmans
Marius Brusselmans
LALucas N. L. Van Aelst
Lucas N. L. Van Aelst
Background: Treatment for breast cancer (BC) frequently involves radiotherapy. Guidelines recommend screening for cardiac adverse events starting 10 years after radiotherapy. The rationale for this interval is unclear. Methods and Results: We aimed to study cardiovascular event rates in the first decade following curative radiotherapy for BC. We compared mortality and cardiovascular event rates with an age‐ and risk factor‐matched control population. We included 1095 patients with BC (mean age 56±12 years). Two hundred and eighteen (19.9%) women died. Cancer and cardiovascular mortality caused 107 (49.1%) and 22 (10.1%) deaths, respectively. A total of 904 cases were matched to female FLEMENGHO (Flemish Study on Environment, Genes and Health Outcomes) participants. Coronary artery disease incidence was similar (risk ratio [RR], 0.75 [95% CI, 0.48–1.18]), yet heart failure (RR, 1.97 [95% CI, 1.19–3.25]) and atrial fibrillation/flutter (RR, 1.82 [95% CI, 1.07–3.08]) occurred more often in patients with BC. Age (hazard ratio [HR], 1.033 [95% CI, 1.006–1.061], P =0.016), tumor grade (HR, 1.739 [95% CI, 1.166–2.591], P =0.007), and neoadjuvant treatment setting (HR, 2.782 [95% CI, 1.304–5.936], P =0.008) were risk factors for mortality. Risk factors for major adverse cardiac events were age (HR, 1.053 [95% CI, 1.013–1.093]; P =0.008), mean heart dose (HR, 1.093 [95% CI, 1.025–1.167]; P =0.007), history of cardiovascular disease (HR, 2.386 [95% CI, 1.096–6.197]; P =0.029) and Mayo Clinic Cardiotoxicity Risk Score (HR, 2.664 [95% CI, 1.625–4.367]; P <0.001). Conclusions: Ten‐year mortality following curative treatment for unilateral BC was mainly cancer related, but heart failure and atrial fibrillation/flutter were already common in the first decade following irradiation. Mean heart dose, pre‐existing cardiovascular diseases, and Mayo Clinic Cardiotoxicity Risk Score were risk factors for cardiac adverse events. These results suggest a need for early dedicated cardio‐oncological follow‐up after radiotherapy.

20 February 2025 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
AVAline Van der Vorst
Aline Van der Vorst
MLMaarten Lambrecht
Maarten Lambrecht
LALucas Van Aelst
Lucas Van Aelst
JVJelle Verhoeven
Jelle Verhoeven
JJJohanna Jacobs
Johanna Jacobs
CWCaroline Weltens
Caroline Weltens

27 April 2026 in Acta Clinica Belgica
Verified
Journal Article
Open access
ADAmélie Dendooven
Amélie Dendooven
AVAnnelore Vandendriessche
Annelore Vandendriessche
PKPriyanka Joseph Koshy
Priyanka Joseph Koshy
FTFrank Timmermans
Frank Timmermans
Marijn M. SpeeckaertMarijn M. Speeckaert
Marijn M. Speeckaert
Michel DelforgeMichel Delforge
Michel Delforge
Amyloidosis is a disorder caused by the extracellular deposition of misfolded protein fibrils, leading to organ dysfunction. Diagnosis remains challenging due to non-specific clinical presentations and the diversity of amyloid subtypes. Accurate identification of the amyloid precursor protein is key for prognostication and treatment strategy. This document aims to provide practical recommendations for the tissue diagnosis of amyloidosis within the Belgian healthcare context. It targets clinicians managing amyloidosis patients and pathologists evaluating biopsies with suspected amyloid deposits. A structured PubMed search ('amyloidosis AND biopsy AND stain*'; 'amyloidosis AND mass spectro*') was conducted in August 2025. After exclusion of case reports, preclinical studies, and Alzheimer-related articles, 298 publications were reviewed. Recommendations were formulated based on available evidence and discussed among Belgian clinical and pathology experts. Key recommendations emphasize that tissue biopsies remain essential for amyloidosis diagnosis and typing. Congo red staining with birefringence and fluorescence confirmation is required. Immunohistochemistry and immunofluorescence are first-line subtyping tools, while mass spectrometry serves as a reference method when results remain inconclusive. Centralization of complex analyses in experienced centres is encouraged. These recommendations promote standardized, early and accurate tissue diagnosis of amyloidosis in Belgium, supporting optimal patient management and harmonization of diagnostic practices across institutions.

14 November 2024 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
LLLorenz Van der Linden
Lorenz Van der Linden
LALucas Van Aelst
Lucas Van Aelst
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
Lorenz Van der Linden, Lucas Van Aelst, Iacopo Olivotto; Pharmacogenetic testing to broaden patient eligibility for mavacamten, European Heart Journal - Ca

8 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
AVAline Van der Vorst
Aline Van der Vorst
JVJelle Verhoeven
Jelle Verhoeven
ABAdinda Baten
Adinda Baten
HJHilde Janssen
Hilde Janssen
LBLander Van Bavel
Lander Van Bavel
CWCaroline Weltens
Caroline Weltens
BackgroundRadiotherapy (RT) improves survival and local control after breast-conserving surgery (BCS) for breast cancer (BC) but can also cause toxicity. Preliminary studies suggest that continuous positive airway pressure (CPAP) reduces organ-at-risk (OAR) doses in left-sided BC RT. This prospective trial evaluates whether CPAP reduces OAR doses in a larger patient cohort, including both left and right-sided cases, and identifies which patients benefit most. Furthermore, this study investigates the feasibility of CPAP in BC RT, by evaluating patient comfort, radiation time, accuracy and reproducibility.MethodsBC patients requiring BCS and RT are prospectively enrolled —left-sided cases with or without regional nodal irradiation (RNI), or right-sided cases requiring RNI. Each patient undergoes an additional CT simulation with CPAP—free breathing (FB) for right-sided cases and deep inspiration breath hold (DIBH) for left-sided cases. Left-sided patients unable to perform DIBH or ≥70 years old are evaluated in FB. Two RT plans (with and without CPAP) are compared. If CPAP reduces mean heart or contralateral breast dose by ≥0.5Gy, or mean lung dose by ≥1Gy, treatment is delivered with CPAP. Patient comfort is assessed through surveys. Sample size calculations indicated that 53 patients are required to detect a ≥0.5Gy reduction in mean heart dose.DiscussionThis is the first large, prospective study to evaluate CPAP in both left- and right-sided BC patients, aiming to demonstrate OAR dose reductions and assess feasibility. The final aim is to provide patient-selection models and guidelines for clinical implementation.Trial registration: The study is registered on Clinicaltrials.gov (NCT07373782).